文献速递肾小球疾病

SARS-CoV-2 mRNA疫苗接种后新发肾小球肾炎的发病率未增加

Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased.
PubMed 文献 · Kidney Int · 2022-09-10

该研究采用全国性回顾性队列和病例-队列设计,利用瑞士所有病理机构处理的天然肾活检数据,分析mRNA-based SARS-CoV-2疫苗接种与新发肾小球肾炎的关联。疫苗接种活动期间(2021年1月至8月)观察到的发病率与基于2015-2019年贝叶斯模型计算的预期发病率无差异(发病率比0.86,95%可信区间0.73-1.02)。在111例新诊断肾小球肾炎成年患者中,38.7%在活检前至少接种过一剂疫苗,与年龄和日历时间匹配的普通瑞士人群的39.5%相比无显著差异;接种疫苗者 vs 未接种疫苗者发生新发活检证实的肾小球肾炎的风险比估计为0.97(95%置信区间0.66-1.42),未达统计学显著。

要点

  • 接种活动期间肾小球肾炎观察发病率与预期发病率无差异,发病率比0.86(95%可信区间0.73-1.02)。
  • 111例新诊断肾小球肾炎患者中38.7%接种过至少一剂疫苗,匹配人群为39.5%。
  • 接种 vs 未接种者风险比0.97(95%置信区间0.66-1.42),未达统计学显著。

核心结论

  • SARS-CoV-2疫苗接种与新发肾小球肾炎无关,大多数时间关联可能为巧合。

研究设计与样本

  • 全国性回顾性队列和病例-队列设计,利用瑞士所有处理天然肾活检的病理机构数据,计算成人瑞士人群IgA肾病、寡免疫坏死性肾小球肾炎、微小病变和膜性肾病的发病率。
  • 病例-队列部分纳入2021年1月至8月间新诊断肾小球肾炎的111例18岁及以上患者。

主要发现

  • 疫苗接种活动期间(2021年1月至8月)观察发病率与基于2015-2019年贝叶斯模型计算的预期发病率无差异,发病率比0.86(95%可信区间0.73-1.02),且任何月份均未超过95%可信区间上限。
  • 111例新诊断肾小球肾炎患者中38.7%在活检前至少接种过一剂疫苗,年龄和日历时间匹配的普通瑞士人群为39.5%。
  • 接种疫苗者 vs 未接种疫苗者发生新发活检证实的肾小球肾炎的风险比估计为0.97(95%置信区间0.66-1.42),未达统计学显著。
  • 接种后4周内发病的肾小球肾炎患者与时间无关发病者临床无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Numerous cases of glomerulonephritis manifesting shortly after SARS-CoV-2 vaccination have been reported, but causality remains unproven. Here, we studied the association between mRNA-based SARS-CoV-2 vaccination and new-onset glomerulonephritis using a nationwide retrospective cohort and a case-cohort design. Data from all Swiss pathology institutes processing native kidney biopsies served to calculate incidence of IgA nephropathy, pauci-immune necrotizing glomerulonephritis, minimal change disease, and membranous nephropathy in the adult Swiss population. The observed incidence during the vaccination campaign (January to August 2021) was not different from the expected incidence calculated using a Bayesian model based on the years 2015 to 2019 (incidence rate ratio 0.86, 95% credible interval 0.73-1.02) and did not cross the upper boundary of the 95% credible interval for any month. Among 111 patients 18 years and older with newly diagnosed glomerulonephritis between January and August 2021, 38.7% had received at least one vaccine dose before biopsy, compared to 39.5% of the general Swiss population matched for age and calendar-time. The estimated risk ratio for the development of new-onset biopsy-proven glomerulonephritis was not significant at 0.97 (95% confidence interval 0.66-1.42) in vaccinated vs. unvaccinated individuals. Patients with glomerulonephritis manifesting within four weeks after vaccination did not differ clinically from those manifesting temporally unrelated to vaccination. Thus, vaccination against SARS-CoV-2 was not associated with new-onset glomerulonephritis in these two complementary studies with most temporal associations between SARS-CoV-2 vaccination and glomerulonephritis likely coincidental.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Diebold M, Locher E, Boide P, et al. Incidence of new onset glomerulonephritis after SARS-CoV-2 mRNA vaccination is not increased. Kidney Int. 2022. PMID: 36096267. doi:10.1016/j.kint.2022.08.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。